0001140361-21-029188.txt : 20210823 0001140361-21-029188.hdr.sgml : 20210823 20210823210039 ACCESSION NUMBER: 0001140361-21-029188 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210819 FILED AS OF DATE: 20210823 DATE AS OF CHANGE: 20210823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIMON IRWIN D CENTRAL INDEX KEY: 0000922748 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38594 FILM NUMBER: 211198303 MAIL ADDRESS: STREET 1: C/O THE HAIN CELESTIAL GROUP INC. STREET 2: 1111 MARCUS AVENUE CITY: LAKE SUCCESS STATE: NY ZIP: 11042 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tilray, Inc. CENTRAL INDEX KEY: 0001731348 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 824310622 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 655 MADISON AVENUE STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: 519.322.8800 MAIL ADDRESS: STREET 1: 655 MADISON AVENUE STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10065 4 1 form4.xml FORM 4 X0306 4 2021-08-19 0001731348 Tilray, Inc. TLRY 0000922748 SIMON IRWIN D C/O TILRAY, INC. 655 MADISON AVENUE, 19TH FLOOR NEW YORK NY 10065 true true President and CEO Class 2 Common Stock 2021-08-19 4 M 0 180251 A 653510 D Class 2 Common Stock 2021-08-19 4 F 0 89495 12.68 D 564015 D Class 2 Common Stock 2021-08-19 4 M 0 72683 A 636698 D Class 2 Common Stock 2021-08-19 4 F 0 36088 12.68 D 600610 D Class 2 Common Stock 2021-08-19 4 M 0 242277 A 842887 D Class 2 Common Stock 2021-08-19 4 F 0 120291 12.68 D 722596 D Restricted Stock Units 2021-08-19 4 M 0 180251 0 D Class 2 Common Stock 180251 0 D Restricted Stock Units 2021-08-19 4 M 0 72683 0 D Class 2 Common Stock 72683 0 D Restricted Stock Units 2021-08-19 4 M 0 242277 0 D Class 2 Common Stock 242277 0 D These shares were retained by Tilray, Inc. ("Tilray") via settlement on a net withholding basis in order to meet the tax withholding obligations of the reporting person in connection with the vesting of installments of restricted stock units ("RSUs") granted to the reporting person on January 22, 2020 and August 12, 2020. None of these shares were sold in an open market transaction. RSUs convert into shares of Tilray Class 2 Common Stock on a one-for-one basis. On August 12, 2020, the reporting person was granted 360,502 RSUs, with 50% vesting on August 12, 2021, and the remaining 50% scheduled to vest on August 12, 2022. On August 19, 2021, the Compensation Committee of Tilray's Board of Directors (the "Compensation Committee") accelerated the vesting of the remaining unvested RSUs. On January 22, 2020, the reporting person was granted 218,038 RSUs, 33.33% of which vested on June 1, 2020; 33.33% of which vested on June 1, 2021; with the remaining 33.34% scheduled to vest on June 1, 2022. On August 19, 2021, the Compensation Committee accelerated the vesting of the remaining unvested RSUs. On January 22, 2020, the reporting person was granted 726,794 RSUs, 33.33% of which vested on June 1, 2020; 33.33% of which vested on June 1, 2021; with the remaining 33.34% scheduled to vest on June 1, 2022. On August 19, 2021, the Compensation Committee accelerated the vesting of the remaining unvested RSUs. The number of beneficially owned derivative securities in Column 9 has been adjusted to exclude 10 RSUs that were inadvertently overreported due to clerical error on the Form 4 filed by the reporting person on June 3, 2021. Following the August 19, 2021 vesting of the 72,683 RSUs described in footnote 4, all such RSUs held by the reporting person were fully vested. The number of beneficially owned derivative securities in Column 9 has been adjusted to exclude 36 RSUs that were inadvertently overreported due to clerical error on the Form 4 filed by the reporting person on June 3, 2021. Following the August 19, 2021 vesting of the 242,277 RSUs described in footnote 5, all such RSUs held by the reporting person were fully vested. /s/ Carl A. Merton, as Attorney-in-Fact for Irwin D. Simon 2021-08-23